Tokyo, April 1 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000060126) titled 'A study on immune-related adverse events developing in malignant tumor patients treated with immune checkpoint inhibitors in our hospital' on April 1.
Study Type:
Observational
Primary Sponsor:
Institute - Saitama Medical University International Medical Center
Condition:
Condition - immune-related adverse events
Classification by malignancy - Others
Genomic information - NO
Objective:
Narrative objectives1 - Immune checkpoint molecules (PD-1, CTLA-4) expressed by T cells function to suppress the activation of T cells themselves, playing a role in stopping the runaway activation of T cells. PD-L1, the ligand for ...